B
Béatrice Weber
Researcher at Paris Descartes University
Publications - 44
Citations - 4350
Béatrice Weber is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Carboplatin & Chemotherapy. The author has an hindex of 19, co-authored 44 publications receiving 3546 citations.
Papers
More filters
Journal ArticleDOI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine,Jonathan A. Ledermann,Frédéric Selle,Val Gebski,Richard T Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo,Philipp Harter,Keiichi Fujiwara,Isabelle Ray-Coquard,Susana Banerjee,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Patricia Pautier,Tomasz Byrski,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Andrés Poveda Velasco,Manuel Rodrigues,Jean-Pierre Lotz,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Medioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie-Christine Kaminsky,Béatrice Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Jonathan Cosin,James Hoffman,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,H. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae Hoon Kim,Jae Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O'Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,Maria Pilar Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez de Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid A. Boere,Petronella B. Ottevanger,Joo-Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan E Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado Herraez,César Mendiola Fernández,Martina Gropp-Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung-Gie Kim,Jae Weon Kim,Jae Weon Kim,Roberto Hegg,Ignace Vergote +110 more
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Journal ArticleDOI
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata,Giovanni Scambia,Dionyssios Katsaros,Ciro Gallo,Eric Pujade-Lauraine,Sabino De Placido,Alessandra Bologna,Béatrice Weber,Francesco Raspagliesi,Pierluigi Benedetti Panici,Gennaro Cormio,Roberto Sorio,Maria Giovanna Cavazzini,Gabriella Ferrandina,Enrico Breda,V. Murgia,Cosimo Sacco,Saverio Cinieri,Vanda Salutari,Caterina Ricci,Carmela Pisano,Stefano Greggi,Rossella Lauria,Domenica Lorusso,Claudia Marchetti,Luigi Selvaggi,Simona Signoriello,Maria Carmela Piccirillo,Massimo Di Maio,Francesco Perrone +29 more
TL;DR: In this paper, a study was conducted to assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drugs given every 3 weeks for patients with advanced ovarian cancer.
Journal ArticleDOI
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Jacobus Pfisterer,Béatrice Weber,Alexander Reuss,Rainer Kimmig,Andreas du Bois,Uwe Wagner,Hugues Bourgeois,Werner Meier,SD Costa,Jens-Uwe Blohmer,Alain Lortholary,S. Olbricht,A. Stähle,Christian Jackisch,Anne-Claire Hardy-Bessard,Volker Möbus,Jens Quaas,Barbara Richter,W. Schröder,Jean-François Geay,Hans-Joachim Lück,Walther Kuhn,Harald Meden,Ulrike Nitz,Eric Pujade-Lauraine,Gineco +25 more
TL;DR: The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival, and this regimen is not recommended as standard of care treatment for ovarian cancer.
Journal ArticleDOI
Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
Andreas du Bois,Béatrice Weber,Justine Rochon,Werner Meier,Alain Goupil,S. Olbricht,Jean-Claude Barats,Walther Kuhn,H. Orfeuvre,Uwe Wagner,Barbara Richter,Hans-Joachim Lueck,Jacobus Pfisterer,SD Costa,W. Schroeder,Rainer Kimmig,Eric Pujade-Lauraine +16 more
TL;DR: Addition of epirubicin to TC did not improve survival or time to treatment failure in patients with advanced epithelial ovarian cancer; therefore, it cannot be recommended for clinical use in this population.